Navigation Links
Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
Date:7/31/2009

SAN CARLOS, Calif., July 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York City on Wednesday, August 5, 2009 at 1:45 p.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until August 31, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC).

NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
3. Nektar Therapeutics Reports First Quarter 2009 Financial Results
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
5. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
6. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
7. Nektar Announces Retirement of Irwin Lerner from Board of Directors
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
9. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
10. Nektar Therapeutics to Webcast R&D Day on November 12th
11. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of ... study of the structure and functions of proteomes or ... tools and technology. Genomics involves the mapping of genes ...
(Date:7/24/2014)... SRI International has been awarded a new ... Allergy and Infectious Diseases (NIAID), part of the National ... therapies for HIV infection and AIDS. The contract supports ... and the complications and opportunistic infections associated with the ... of HIV. According to the World ...
(Date:7/24/2014)... Three companies from the angelMD network were ... Competition. Out of 700 competition entrants, Chiron Health, Litesprite, ... round. In this round twenty teams are invited to ... mentoring from thought-leaders and medical entrepreneurs from all over ... commitment to the Livestrong vision around the Big C ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... forecasts of its potential revenue from new rodenticide research ... investors and analysts on July 22, 2014, Neogen,s CEO ... regarding this research. "It was my intent ... the potential of a new type of rodenticide, but ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... Introduces RESPeRATE Hypertension ... Device Into Country,s Retail Market, NEW YORK ... today announced that its RESPeRATE(R) hypertension treatment device,clinically-proven ... will launch into retail distribution in the United ...
... Lower Strength of Approved Constipation Drug Offers Potential Treatment ... Option to Americans Suffering from IBS-C, ... SCMP ) today announced that the supplemental,New Drug Application (sNDA) ... treatment of irritable bowel syndrome with,constipation (IBS-C) has been accepted ...
... , WHAT: DENTAL IMPLANT MARKET INSIGHTS ... presentation), WHEN: ... from Millennium Research Group, TO ENROLL: Please use the link below ... 416-364-7776 ext. 123 Millennium Research Group ...
Cached Biology Technology:InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 2InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 3InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 4FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 2FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 3FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 4FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 5Dental Implant Market Insights Webinar 2
(Date:7/25/2014)... engineering at the University of Houston, has written ... organ development., "Introduction to Tissue Engineering: Applications and ... the field of artificial organ development. Metin Akay, ... UH, served as a series editor on the ... published books on the subject of growing artificial ...
(Date:7/25/2014)... of diffusion tensor tractography (DTT), which is derived ... estimation for three motor tracts, such as the ... pathway became possible. The corticospinal tract is known ... function in the human brain. Several studies have ... transtentorial herniation. In addition, some studies have demonstrated ...
(Date:7/25/2014)... 25, 2014 Biometrics industry expands ... to digital technology for online & commerce payments while ... (NASDAQ: GOOG ), LifeLock Inc. (NYSE: ... ), Apple Inc. (NASDAQ: AAPL ) and ... NXTD) a biometric authentication company focused on the growing ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... of studying up close the symbiotic relationship between a mosquito-sized ... advanced the scientific understanding of biological diversity. Jeffrey ... or more organisms that can be parasitic or mutualistic ... and competition. The Proceedings of the Royal ...
... virtual reality, going beyond virtual spaces in which people can ... the sense of touch. The technology would make it ... in other locations. When a patient pushes down on a ... down with the same force, as if the patient were ...
... and engineers in Antarctica, funded by the National Science Foundation ... past climate and greenhouse gases in the atmosphere that extends ... Sheet (WAIS), the ice containing the record is known as ... make up the core contain uniquely detailed information on past ...
Cached Biology News:Pirate-like flies connect symbiosis to diversity 2UT Dallas researchers pushing the boundaries of virtual reality 2UT Dallas researchers pushing the boundaries of virtual reality 3Antarctic ice core contains unrivaled detail of past climate 2Antarctic ice core contains unrivaled detail of past climate 3
... Epithelial and endothelial cells-directed ... a RGD peptide-conjugated polyethylenimine which ... integrin-expressing epithelial and endothelial cells. ... in cell-cell and cell-matrix adhesion ...
... WinMelt software is used ... of any DNA sequence up ... in optimizing placement of primers ... detection by denaturing gradient gel ...
Request Info...
... To score SNPs, Polymorphic uses proven, ... standard in DNA analysis. We use high ... can be confirmed by sequencing in both ... provides sequence context information, further confirming the ...
Biology Products: